Indy hospitals healthy despite sequester
While rural hospitals face sharp reductions in their operating incomes, most of the four major hospital systems based in Indianapolis will see only a marginal impact on their finances.
While rural hospitals face sharp reductions in their operating incomes, most of the four major hospital systems based in Indianapolis will see only a marginal impact on their finances.
The sequestration plan kicking in Friday will chop Medicare payments to hospitals, doctors and nursing homes by 2 percent, beginning April 1. One study estimates that the cuts could result in 10,000-plus job losses in Indiana alone.
The five-year trend of physician practices marrying up with hospitals has made it harder and harder for independent physician practices to spend time in more than one hospital system.
Paul Halverson has been appointed founding dean of the new Indiana University Richard M. Fairbanks School of Public Health at IUPUI. Halverson, 54, has served as director and state health officer for the Arkansas Department of Health since 2005. Prior to his work in Arkansas, Halverson held several positions at the Centers for Disease Control and Prevention. Halverson earned a bachelor’s degree in communication and a master’s degree in health services administration from Arizona State University. He also earned a doctorate in public health from the University of North Carolina.
Jay Brehm has been appointed senior vice president of strategic planning and business development for Franciscan Alliance, a Mishawaka-based hospital system. Brehm currently is the chief financial officer at Franciscan St. Francis Health, which operates Franciscan’s three Indianapolis-area hospitals. Brehm holds a bachelor’s degree in accounting and an MBA from Ball State University.
Dr. Thomas Wisler has joined Franciscan Physician Network McFarland Gynecologic Specialists on the south side. Wisler received a bachelor’s degree from the University of Florida and a medical degree from Creighton University School of Medicine.
Titus Schleyer has been named to lead the Center for Biomedical Informatics at Indianapolis-based Regenstrief Institute. Schleyer is an associate professor of dental public health at the University of Pittsburgh and founding director of the Center for Dental Informatics in the School of Dental Medicine. Schleyer earned doctorates in dental medicine and molecular biology at the University of Frankfurt am Main in Germany. He subsequently received a second dental degree and an MBA in health administration from Temple University in Philadelphia.
Anthem Blue Cross and Blue Shield has selected Community Health Network to be the “exclusive provider” for a new kind of health insurance plan—a sharp departure from Anthem’s typical strategy of offering the broadest network of hospitals and doctors.
Across the four largest hospital systems in central Indiana, six physicians received more than $1 million in compensation in 2011 while two others received more than $900,000 and nine others received $700,000 or more, according to the hospitals’ most recent reports to the IRS.
Suzanne Clifford has been named executive vice president of behavioral health at Community Health Network, beginning Feb. 25. She replaces Eric Crouse, who is retiring after nearly 34 years at Community. Clifford most recently has led Inspiring Transformations Inc., an Indianapolis-based consulting firm she founded that focused on the delivery of mental health and substance abuse care. Before that, Clifford was director of the Indiana Division of Mental Health and Addiction, and also served stints at Eli Lilly and Co. and General Motors Corp. She holds a bachelor’s in industrial and systems engineering from The Ohio State University and an MBA from Indiana University.
St. Vincent Health has appointed Dr. Craig Wilson chief medical officer of St. Vincent Medical Center Northeast, which is adding 50 inpatient beds and will change its name to St. Vincent Fishers Hospital on April 8. Wilson will remain executive director of hospitalist services at St. Vincent Indianapolis Hospital. Wilson completed his medical degree at the University of Queensland, Australia.
The Indiana Medical Device Manufacturers Council appointed Peggy Welch as its executive director, effective immediately. Welch was a Democratic state legislator from Bloomington for 14 years and works part time as an oncology nurse at the Indiana University Health Bloomington Hospital.
Dr. Nahid Shahrooz has joined the newly established Franciscan Physician Network Dermatology Specialists. Formerly associated with Shahrooz Dermatology and the Indianapolis Institute for Plastic Surgery, she specializes in the surgical removal of skin tumors, cancers and lesions. Shahrooz earned her medical degree at Mashad Medical School in Iran.
Dr. Janice Bilby has joined Franciscan Physician Network Greenwood Parke Family Medicine. Bilby received her undergraduate degree in biology from Ball State University and her medical degree from the Indiana University School of Medicine.
With the surname Tucker, Travis Tucker seemed destined to work in real estate.
“I get that all the time,” said Tucker, who is not related to the family that founded the locally headquartered F.C. Tucker Co. real estate brokerage, but instead is a vice president at Duke Realty Corp., where he handles health care projects in the Midwest.
The Franciscan Alliance hospital system has signed a deal with Philadelphia-based health insurer Cigna Corp. to offer an accountable care plan to Cigna’s customers in the Indianapolis area. Mishawaka-based Franciscan will use the same accountable care organization it formed in 2011 to work with the federal Medicare program. That organization includes Franciscan hospitals in Carmel, Indianapolis and Mooresville, as well as 600 physicians in central Indiana. Franciscan and Cigna will rely heavily on case managers, who will help patients, especially those with chronic diseases, navigate the health system. The case managers will use Cigna data to identify patients in need of such attention and will in some cases refer patients to Cigna’s health management and wellness programs.
Warsaw-based DePuy Orthopaedics Inc. kept selling an artificial hip implant even after the doctors it paid as consultants on the product had begun abandoning it and after the product had failed an internal test, according to internal company documents disclosed in a legal case and summarized by The New York Times. DePuy, a subsidiary of New Jersey-based Johnson & Johnson, recalled the troubled hip implant, called the Articular Surface Replacement, or ASR, in 2010. The company has been the target of 10,000 lawsuits filed by patients who had to receive a second hip implant after the ASR failed. The device has been prone to shedding large amounts of metallic debris inside patients. DePuy’s own internal estimates show they expected the ASR to fail in 40 percent of patients within five years of their hip-implant surgery.
Greenwood-based Elona Biotechnologies Inc., which has been trying to bring a generic version of insulin to market, is running out of cash and struggling to find new investors. The company told Greenwood officials of its financial troubles earlier this month, which prompted the Greenwood Redevelopment Commission to vote Jan. 17 to declare Elona in default on $8.4 million of economic development incentives the city gave the company in 2010. Wendy Brewer, an attorney for the Greenwood Redevelopment Commission, said one potential investor in Elona wants the company’s exposure under the incentive programs altered as a condition of investing in Elona. “We’re continuing to talk to them,” Brewer said, adding that the company’s finances dictate that a decision be made in a couple of weeks. Greenwood loaned $6.4 million to help Elona build a 50,000-square-foot, $28 million insulin-production plant in Greenwood and hire 70 workers. The city also gave Elona $1.5 million to help it win approval for its insulin from the U.S. Food and Drug Administration and $500,000 for equipment. So far, Brewer said, Elona has made no progress on its jobs commitments. Elona, founded by a former Eli Lilly and Co. scientist, has made its business doing contract drug manufacturing for other firms. But its growth plans hinged on making a generic version of insulin, something that was not allowed in the United States until the 2010 passage of the Patient Protection & Affordable Care Act. That law called for a pathway for “biosimilar” versions of biotech drugs, including insulin. As it stands now, a drug such as Lilly’s Humulin insulin faces no generic competition even though its patent expired in 2001. Nearly a year ago, the FDA issued draft guidance on “biosimilar” drugs that indicated it would require additional clinical trials of a biosimilar drug. That means a company like Elona would have to spend significant money to test its drug in patients before the FDA would declare it similar to an existing insulin. Calls to Elona founders Ron and Donna Zimmerman were not returned Tuesday morning.
WellPoint Inc. ended the year on a high note, posting fourth-quarter sales and profit that exceeded Wall Street’s expectations. The Indianapolis-based health insurer earned $464 million, or $1.51 per share, in the three months ended Dec. 31, a 38-percent leap from the same quarter a year earlier. Excluding investment gains and one-time charges, WellPoint would have earned $1.03 per share. On that basis, analysts were expecting 95 cents per share. Membership in WellPoint’s health plans shot up nearly 8 percent in the fourth quarter to more than 36 million nationwide. That represented a net gain of more than 2.6 million customers. The increase was entirely attributable to WellPoint’s $4.9 billion acquisition of Virginia-based Amerigroup Corp., which added 2.7 million members in Medicaid plans. But the Blue Cross Blue Shield insurer on Wednesday gave analysts a conservative forecast for 2013, due in part to a daunting list of expenses it could face. WellPoint will spend roughly $300 million this year preparing for coverage expansions under the health care overhaul coverage and changes to its Medicare Advantage business. The insurer also expects to spend as much as $125 million integrating Amerigroup into its business, and it says it could take hits from flu claims, possible cuts to Medicare funding and an increase in health care use. Counting those expenses, WellPoint expects to earn at least $7.60 per share in 2013 compared to the $8.18 per share it earned last year.
St. Vincent Health will add air medical service at Rush Memorial Hospital in Rushville. The new StatFlight helicopter base, scheduled to open in late April or early May, will be St. Vincent's fourth helicopter base in Indiana. The others are located in Anderson, Danville, North Vernon and West Lafayette. St. Vincent contracts with PHI Air Medical LLC to operate its StatFlight air medical service.
The Community Health Network hospital system has created a new partnership with Indianapolis-based Lutheran Child and Family Services to provide treatment for children who have experienced trauma and are dealing with behavioral challenges. Indianapolis-based Community will help Lutheran manage the behavioral health services for children and adolescents at Lutherwood, a youth residential treatment facility, and Trinity House, a transitional group home for young men. The collaboration also will include community-based programs previously managed separately under Indianapolis-based Gallahue Community Mental Health Center and Lutheran. Lutheran will continue to offer spiritual care programs of its own for children and their families. Community serves more than 25,000 behavioral health patients each year. Its behavioral health unit employs more than 600 physicians, psychologists, advance practice nurses, psychiatric nurses, therapists, counselors, life skills specialists and care managers.
Announcements Brad Banks, J.D. and Adam Brower, J.D. have opened their legal practice, Banks & Brower LLC, in northwest Indianapolis, specializing in the practice areas of criminal, DUI, family law, business law, construction law, and education/school law. Phone: 870-0019; Email: [email protected]. Weston Sponseller has launched Crossroads Chem-Dry®, providing Chem-Dry services to all of Marion County, […]
Franciscan St. Francis Health and American Health Network continue to get deeper into the accountable care organization concept being promoted by the federal Medicare program under the 2010 health reform law.
State officials are expected to sign off on a one-year extension of the Healthy Indiana Plan started by Gov. Mitch Daniels, sparing the program’s roughly 40,000 enrollees a lapse in coverage, according to the Associated Press. Family and Social Services Administration spokeswoman Marni Lemons said the state received the needed paperwork from the federal government on Dec. 13. The federal Centers for Medicare and Medicaid Services agreed to a waiver that would allow the state to continue the program unchanged for a year, Lemons said. The HIP program offers health savings accounts to the working poor, requiring them in most cases to pay a monthly contribution to their savings accounts. The Daniels administration had sought a three-year extension of the program via the Centers for Medicare and Medicaid Services' waiver process, but the federal government replied in July with an offer of one year and a request that the state end mandatory contributions from enrollees. Lemons said the new offer allows Indiana to continue collecting a monthly contribution, but did not say why CMS reversed its position.
Milliman Inc., an actuarial and consulting firm, announced Friday morning that it plans to add 26 jobs in Indianapolis by 2017 as part of a $2 million expansion. The Seattle-based company, which has 54 offices worldwide, said the investment will go toward installing additional technology at its 25,000-square-foot office in downtown’s Chase Tower. Milliman already had 55 employees at the location and has begun hiring additional actuarial consultants. The Indiana Economic Development Corp. said it will provide Milliman up to $400,000 in performance-based tax credits and up to $97,000 in training grants based on the company's job-creation plans. Milliman has had a presence in Indianapolis since 1965.
A south-side entrepreneur unveiled plans Thursday to convert the old St. Francis Hospital in Beech Grove into a $20 million mixed-use senior-living development. Joe Wolfla, who helped lead the reintroduction last year of the chocolate beverage Choc-ola, announced the project at a Beech Grove Chamber of Commerce event. Dubbed Franciscan Place, the development will feature 150-plus apartments, shops and a restaurant in the old hospital. Wolfla purchased the 14-acre site from Franciscan St. Francis for $10. The property became available in March after the Catholic hospital system ended all inpatient operations at the facility. Franciscan announced five years ago that it would consolidate its Beech Grove operations into an expanded facility seven miles south, near Interstate 65 and Emerson Avenue. The Beech Grove hospital was founded in 1914 by the Sisters of St. Francis of Perpetual Adoration, an order of nuns based in Mishawaka. But it fell victim to the need for hospitals to attract patients using private health insurance, which pays generous prices compared to government-sponsored health plans such as Medicare and Medicaid.
Eli Lilly and Co. last week halted one clinical trial for a rheumatoid arthritis drug and announced a new trial for an Alzheimer’s drug. Both moves are potential setbacks for the Indianapolis-based drugmaker's product pipeline. Lilly stopped one of three Phase 3 trials it was conducting on the drug tabalumab, because it failed to show efficacy against rheumatoid arthritis. The other two trials are proceeding, but Lilly is holding off on enrolling new patients until more analyses are finished early next year. Lilly is still evaluating tabalumab in systemic lupus erythematosus. The company said it expects to take a pretax charge of $20 million to $35 million in the fourth quarter, or about 2 cents a share after tax. Lilly also announced that it needs to run another Phase 3 trial of its experimental Alzheimer's treatment solanezumab. That means it will likely take another five years before Lilly can launch solanezumab—assuming the new trial confirms and strengthens the signs that the drug helps slow the progression of Alzheimer’s in patients with mild forms of the disease. Lilly said the study will begin no later than the third quarter of 2013. With many other companies also testing Alzheimer’s drugs in Phase 3 trials, the delay means another company could beat Lilly in its quest to launch the first drug to successfully reverse the course of the memory-sapping disease.